SCHEMBL25877473

SCHEMBL25877473

CC1(Nc2cc(C(N)=O)ccc2[N+](=O)[O-])COC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
PARP1 P09874 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ATM Q13315 1/20 0.44
MAPT P10636 5/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 3/20 0.42
GAA P10253 2/20 0.42
PKM P14618 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
TSHR P16473 2/20 0.42
CTPS1 P17812 1/20 0.42
SIRT2 Q8IXJ6 2/20 0.41
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877422 0.86 VCAM1 (0.48) LMNAALDH1A1HTTKMT2APKM
SCHEMBL25877480 0.79 MAPT (0.38) ALDH1A1MAPTKDM4EKMT2APKM
SCHEMBL25877683 0.79 HTT (0.53) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL27944435 0.78 HCAR3 (0.56) LMNAPARP1SMN1; SMN2ALDH1A1ATM
SCHEMBL25877435 0.76 ALDH1A1 (0.42) LMNAALDH1A1MAPTKMT2AGAA
SCHEMBL25877451 0.75 VCAM1 (0.44) LMNAALDH1A1MAPTKMT2APKM
SCHEMBL30623210 0.75 VCAM1 (0.50) LMNAALDH1A1HTTKMT2APKM
SCHEMBL26122443 0.75 VCAM1 (0.50) LMNAALDH1A1HTTKMT2APKM
SCHEMBL6170977 0.75 PARP1 (0.53) LMNAPARP1SMN1; SMN2ALDH1A1ATM
SCHEMBL25877386 0.75 MAPK1 (0.47) LMNASMN1; SMN2ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B LMNA 387/4885PARP1 50/4885SMN1; SMN2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.